0000000000462094

AUTHOR

Frédérique Jacobs

showing 2 related works from this author

European expert opinion on the management of invasive candidiasis in adults

2011

Item does not contain fulltext This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad ans…

Invasive mycoses and compromised host Translational research [N4i 2]AdultMicrobiology (medical)medicine.medical_specialtyAntifungal Agentsmedicine.medical_treatmentPlacebo-controlled studyMEDLINEInvasive mycoses and compromised host Infection and autoimmunity [N4i 2]MicrobiologyMedicineHumanscandidaemiaCandidiasis InvasiveguidelinesIntensive care medicineWatchful Waitingtherapybusiness.industryTreatment optionsPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]General MedicineInvasive candidiasisComparative trialAntibiotic Prophylaxismedicine.diseaseOptimal managementEuropeIntensive Care UnitsInfectious DiseasesconsensusExpert opinioncandidabusinessWatchful waitingClinical Microbiology and Infection
researchProduct

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

2007

Summary Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentLipoproteinsAmphotericin B/ therapeutic useMicrobial Sensitivity TestsLipoproteins/ therapeutic usePeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BPeptides Cyclic/ therapeutic usemedicineHumansAdverse effectMycosisFungemiaCandidiasis/complications/ drug therapy/microbiologyAPACHEAgedddc:616Aged 80 and overVoriconazolebusiness.industryAntifungal Agents/ therapeutic useCandidiasisMicafunginGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseApacheSurgeryTreatment OutcomechemistryMicafunginFemaleCaspofunginbusinessFluconazolemedicine.drugThe Lancet
researchProduct